CIK 1600175
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2019-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 63.26% | 26 |
| Pharmaceuticals & Biotechnology | 25.90% | 23 |
| Life Sciences Tools & Services | 10.84% | 5 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | IBB | ISHARES TR | Unclassified | 26.53% |
| 2 | DIREXION DAILY S&P BIOTECH BULL 3X ETF | Unclassified | 6.58% | |
| 3 | MTD | METTLER TOLEDO INTERNATIONAL INC/ | Health Care | 4.86% |
| 4 | BMY | BRISTOL MYERS SQUIBB CO | Health Care | 3.57% |
| 5 | SEATTLE GENETICS INC | Unclassified | 3.28% | |
| 6 | ILMN | ILLUMINA, INC. | Health Care | 3.06% |
| 7 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Health Care | 2.99% |
| 8 | IONS | IONIS PHARMACEUTICALS INC | Health Care | 2.57% |
| 9 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Health Care | 2.35% |
| 10 | ALEXION PHARMACEUTICALS INC | Unclassified | 2.08% |
28/54 names classified · sector 36.7% of weight · industry 36.7% · mkt cap 34.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 36.7% of the book is sector-classified (unclassified names shown, never dropped).
Only 28% of book weight classified — the grid is NOT representative of the whole book.
Classified: 28.0% of book weight (19/32 names) · unclassified 72.0%: , IBB, IONS, PRQR, ASND, QURE, CRSP, MGNX, NTLA, CRL +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | IBBISHARES TR | 125,000 | $12M | 26.5% | HOLD |
| 2 | DIREXION DAILY S&P BIOTECH BULL 3X ETF | 99,855 | $3M | 6.6% | HOLD |
| 3 | MTDMETTLER TOLEDO INTERNATIONAL | 3,235 | $2M | 4.9% | HOLD |
| 4 | BMYBRISTOL-MYERS SQUIBB CO | 33,000 | $2M | 3.6% | HOLD |
| 5 | SEATTLE GENETICS INC | 18,020 | $2M | 3.3% | HOLD |
| 6 | ILMNILLUMINA INC | 4,721 | $1M | 3.1% | HOLD |
| 7 | VRTXVERTEX PHARMACEUTICALS INC | 8,279 | $1M | 3.0% | HOLD |
| 8 | IONSIONIS PHARMACEUTICALS INC | 20,124 | $1M | 2.6% | HOLD |
| 9 | ALNYALNYLAM PHARMACEUTICALS INC | 13,684 | $1M | 2.3% | ADD 2% |
| 10 | ALEXION PHARMACEUTICALS INC | 9,933 | $973,000 | 2.1% | HOLD |
| 11 | QIAGEN NV | 28,858 | $951,000 | 2.0% | HOLD |
| 12 | SPARK THERAPEUTICS INC | 9,699 | $941,000 | 2.0% | HOLD |
| 13 | FORTRESS BIOTECH INC | 613,551 | $865,000 | 1.8% | ADD 162% |
| 14 | PRQRPROQR THRAPEUTICS N V | 138,461 | $798,000 | 1.7% | HOLD |
| 15 | INCYINCYTE CORP | 10,659 | $791,000 | 1.7% | HOLD |
| 16 | EXACT SCIENCES CORP | 8,534 | $771,000 | 1.6% | HOLD |
| 17 | REGNREGENERON PHARMACEUTICALS | 2,439 | $677,000 | 1.4% | ADD 10% |
| 18 | BMRNBIOMARIN PHARMACEUTICAL INC | 9,700 | $654,000 | 1.4% | ADD 3% |
| 19 | DECIPHERA PHARMACEUTICALS IN | 18,631 | $632,000 | 1.3% | HOLD |
| 20 | ASNDASCENDIS PHARMA A/S | 6,190 | $596,000 | 1.3% | HOLD |
| 21 | QUREUNIQURE NV | 14,215 | $560,000 | 1.2% | HOLD |
| 22 | CELGENE CORP | 5,625 | $559,000 | 1.2% | HOLD |
| 23 | CRSPCRISPR THERAPEUTICS AG | 13,214 | $542,000 | 1.2% | HOLD |
| 24 | EPIZYME INC. | 50,378 | $520,000 | 1.1% | HOLD |
| 25 | Amarin Corp PLC | 33,641 | $510,000 | 1.1% | ADD 102% |
| 26 | BLUEPRINT MEDICINES CORP | 6,780 | $498,000 | 1.1% | HOLD |
| 27 | AUDENTES THERAPEUTICS INC. | 17,339 | $487,000 | 1.0% | HOLD |
| 28 | G1 THERAPEUTICS INC | 20,844 | $475,000 | 1.0% | HOLD |
| 29 | GLOBAL BLOOD THERAPEUTICS INC | 9,479 | $460,000 | 1.0% | HOLD |
| 30 | BIOHAVEN PHARMACTL HLDG CO L | 10,852 | $453,000 | 1.0% | HOLD |
| 31 | ARENA PHARMECEUTICALS INC | 9,770 | $447,000 | 1.0% | HOLD |
| 32 | ACADACADIA PHARM | 12,005 | $432,000 | 0.9% | HOLD |
| 33 | GW PHARMACEUTICALS PLC | 3,674 | $423,000 | 0.9% | HOLD |
| 34 | ZOGENIX INC. | 9,725 | $389,000 | 0.8% | HOLD |
| 35 | MGNXMACROGENICS INC | 30,075 | $384,000 | 0.8% | HOLD |
| 36 | NTLAINTELLIA THERAPEUTICS INC | 28,490 | $380,000 | 0.8% | HOLD |
| 37 | TECHBIO-TECHNE CORP | 1,551 | $303,000 | 0.6% | HOLD |
| 38 | IQVIQVIA HLDGS INC | 1,985 | $297,000 | 0.6% | HOLD |
| 39 | AMGNAMGEN INC | 1,518 | $294,000 | 0.6% | ADD 9% |
| 40 | NBIXNEUROCRINE BIOSCIENCES INC | 3,127 | $282,000 | 0.6% | ADD 4% |
| 41 | Checkpoint Therapeutics Inc Com | 112,760 | $281,000 | 0.6% | HOLD |
| 42 | CRLCHARLES RIV LABS INTL INC | 2,112 | $280,000 | 0.6% | HOLD |
| 43 | UTHRUnited Therapeutics Corp. | 3,498 | $279,000 | 0.6% | NEW |
| 44 | GRFSGRIFOLS S A | 13,196 | $264,000 | 0.6% | HOLD |
| 45 | BIIBBIOGEN INC | 1,123 | $261,000 | 0.6% | HOLD |
| 46 | INTERCEPT PHARMACEUTICALS IN | 3,926 | $261,000 | 0.6% | TRIM −33% |
| 47 | GILDGILEAD SCIENCES INC | 4,082 | $259,000 | 0.6% | HOLD |
| 48 | LGNDLIGAND PHARMACEUTICALS INC | 2,428 | $242,000 | 0.5% | ADD 15% |
| 49 | NKTRNEKTAR THERAPEUTICS COM NEW | 12,927 | $235,000 | 0.5% | ADD 3% |
| 50 | EXELEXELIXIS INC | 13,132 | $232,000 | 0.5% | ADD 15% |
| 51 | ALKSALKERMES PLC | 11,632 | $227,000 | 0.5% | NEW |
| 52 | RAREULTRAGENYX PHARMACEUTICAL IN | 5,064 | $217,000 | 0.5% | HOLD |
| 53 | FIBROGEN INC | 5,742 | $212,000 | 0.5% | ADD 18% |
| 54 | SOCIETAL CDMO INC | 11,353 | $126,000 | 0.3% | HOLD |
Where this firm's principals came from and which firms its alumni went on to found.
